tailieunhanh - Báo cáo khoa học: "Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death. | Available online at http content 10 6 316 University of Pittsburgh Department of Critical Care Medicine Evidence-Based Medicine Journal Club EBM Journal Club Section Editor Eric B. Milbrandt MD MPH Journal club critique Drotrecogin alfa activated should not be used in patients with severe sepsis and low risk for death Sanjay Gupta 1 Eric B. Milbrandt 2 and Lakshmipathi Chelluri3 1 Clinical Fellow Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA 2 Assistant Professor Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA 2 Professor Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA Published online 3 November This article is online at http content 10 6 316 2006 BioMed Central Ltd Critical Care 2006 10 316 DOI 101186 cc5071 Expanded Abstract Citation Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL Francois B Guy JS Bruckmann M Rea-Neto A Rossaint R Perrotin D Sablotzki A Arkins N Utterback BG Macias WL Drotrecogin alfa activated for adults with severe sepsis and a low risk of death. N Engl J Med 2005 353 1332-1341 1 . Background In November 2001 the Food and Drug Administration FDA approved drotrecogin alfa activated DrotAA for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death. Methods Design and setting Double-blind randomized placebo-controlled trial conducted in 516 centers in 34 countries. Subjects Adult patients with severe sepsis and a low risk of death defined by an Acute Physiology and Chronic Health Evaluation APACHE II score 25 or single-organ failure . Intervention Subjects were randomized to receive an intravenous infusion of placebo or DrotAA 24 jg per kilogram of body weight per hour for 96 hours. Measurements The prospectively .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.